GNLX

Genelux Corporation

12.62 USD

Last updated Dec 6, 17:52 UTC

Yesterday HIGH

$13.34

Yesterday LOW

$11.01

52w HIGH

$40.98

52w LOW

$5.35

EPS

-0.2

PE

-63.10

Next Earnings

Dec 19, 2023

Overview News Insider Transactions Government Trades

Genelux Corporation stock is down -9.66% since 30 days ago. The next earnings date is Dec 19, 2023. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 100% of the previous 1 December’s closed higher than November. 100% of analysts rate it a buy.

Genelux is a clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Our principal executive offices are located at 2625 Townsgate Road, Suite 230, Westlake Village, California.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

www.genelux.com

Lisa Levin

Tue Jul 25, 2023

Why Alaska Air Group Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Gainers Aurora Acquisition Corp. (NASDAQ: AURC) shares jumped 192% to $30.54.
Lisa Levin

Tue Jul 25, 2023

Xerox, Logitech International, Packaging Corporation of America And Other Big Stocks Moving Higher On Tuesday

U.S. stocks traded higher, with the Nasdaq Composite gaining around 75 points on Tuesday. Here are some big stocks recording gains in today’s session.
Benzinga Newsdesk

Mon Jul 10, 2023

Genelux Corp Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology

Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced the publication in Frontiers in Immunology of positive results from a Phase 1 trial exploring intrapleural delivered
Benzinga Insights

Tue Jun 27, 2023

12 Health Care Stocks Moving In Tuesday's Intraday Session
Bill Haddad

Thu Jun 22, 2023

Genelux Corporation Set To Join Russell 3000 And Russell 2000 Indexes Effective June 26, 2023
AJ Fabino

Fri Jun 16, 2023

Cava Stock Makes A Stand In Mixed IPO Landscape: Where Does It Rank Against Other 2023 Wall Street Debuts?

In a year that’s seen a sharp decline in initial public offerings, Washington, D.C.-based Mediterranean restaurant chain Cava Group (NYSE: CAVA) made a striking first public appearance on the New York Stock Exchange on Thursday, with shares opening at $42,
Benzinga Newsdesk

Wed Jun 14, 2023

Pancreatic Cancer Action Network Urges Advocates From All 50 States To Call On Congress To Increase Federal Funding For Pancreatic Cancer Research

Federal Funding Increases Fuel Research Progress and Help Improve Patient OutcomesLOS ANGELES, June 14, 2023 /PRNewswire/ -- The Pancreatic Cancer Action Network (PanCAN), a leading pancreatic cancer patient
Benzinga Newsdesk

Mon Jun 12, 2023

Genelux Corporation Announces $18M Private Placement; 900K Shares At $20/Share
richadhand@benzinga.com

Fri Jun 9, 2023

Benchmark Maintains Speculative Buy on Genelux, Raises Price Target to $38

Benchmark analyst Bruce Jackson maintains Genelux (NASDAQ:GNLX) with a Speculative Buy and raises the price target from $10 to $38.
Benzinga Newsdesk

Thu May 25, 2023

Genelux Reports Publication Of Positive Topline Data From Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) In Platinum-Resistant or Refractory Ovarian Cancer

Phase 2 Trial of Olvi-Vec-primed immunochemotherapy in heavily pre-treated patients.Met primary endpoint of objective response rate with deep and durable responses

HC Wainwright & Co.

Mon Nov 27, 07:22

buy

initial
Benchmark

Fri Nov 24, 10:40

buy

confirm

Advanced Data Unlock

Yu Tony, VP, Clinical Trial Operations

Tue Nov 21, 2023

GNLX Recent Insider Trades and Stock Chart

18,665 shares sold
Yu Tony, VP, Clinical Trial Operations

Fri Nov 17, 2023

GNLX Recent Insider Trades and Stock Chart

3,541 shares sold
Yu Tony, VP, Clinical Trial Operations

Mon Nov 20, 2023

GNLX Recent Insider Trades and Stock Chart

14,594 shares sold